

September 23, 1965

Dr. J. Robert Hewson  
McNeil Laboratories  
Camp Hill Road  
Fort Washington, Pennsylvania 19034

Dear Dr. Hewson:

We have completed the trifluoperidol study and have rewritten the report. The full draft is being retyped and will be sent to you separately. It is our intention to condense this draft and submit it to one of the journals for publication. Have you any suggestions as to whom we may send it?

In this draft you will note that we have made some of the corrections which you have suggested. You will note, however, that we have included in this draft a paragraph about our butaperazine experience. The failure of the subjects to respond to this potent phenothiazine as well as trifluoperidol reinforced my belief that we had selected a group of therapy resistant subjects. In reviewing the psychopathological data we did find that various disturbances showed amelioration. We did visit Dr. Deniker in Paris last month and found that his population was a much more acute one and we believe that his favorable impression of the butyrophenones is related to the population differences.

In the meantime, we have collected all the data of our laboratory studies and have written individual case protocols. Both of these are being prepared and will be sent to you.

During the last visit you requested some additional data and it is unclear as to what we should make available to you. We have many rating scales, and the full EEG records. Is any of this material to be duplicated?

I would appreciate your calling me or having your clinical research associate visit me so that this project can be completed.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp